Form 4: Arrowhead CMO Plans Future Stock Sale Under 10b5-1 Plan

Arrowhead Pharmaceuticals' Chief Medical Officer, James C. Hamilton, filed a Form 4 detailing planned sales of 40,164 common shares in January 2026 under a 10b5-1 plan.

Summary

• James C. Hamilton, Chief Medical Officer of Arrowhead Pharmaceuticals, Inc. (ARWR), reported planned sales of common stock.
• The transactions are scheduled for January 5, 2026.
• A total of 40,164 shares of common stock are planned to be sold across multiple transactions.
• The sales are being conducted pursuant to a Rule 10b5-1 trading plan, adopted in accordance with SEC regulations.
• A portion of the disposition is intended to satisfy tax withholding obligations.
• The weighted average sale prices for these planned transactions range from $61.24 to $68.00 per share.
• Following these planned transactions, Mr. Hamilton will beneficially own 171,958 shares of common stock.
• The reported beneficial ownership includes shares underlying Restricted Stock Units (RSUs) that are still subject to certain vesting conditions.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it involves insider selling, it's a pre-planned transaction under a 10b5-1 plan and partially for tax obligations, which are routine and expected reasons for such dispositions, rather than a signal of negative sentiment about the company's future. The future transaction date also reduces immediate market impact.

Positives

• The sales are pre-planned under a Rule 10b5-1 trading plan, indicating a structured and pre-determined approach rather than an immediate reaction to market conditions.
• A portion of the sales is explicitly for satisfying tax withholding obligations, which is a common and expected reason for insider dispositions, particularly related to vesting equity awards.

Negatives

• Insider selling, even if planned, can sometimes be perceived negatively by the market as it reduces management's direct equity stake in the company, although the impact is mitigated by the 10b5-1 plan and tax-related reasons.

Risks

• Potential for negative market perception due to insider selling, despite the existence of a 10b5-1 plan and stated tax obligations, which could lead to minor short-term sentiment shifts.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's operational or financial performance, beyond the scheduled future stock transactions.

Management Comments

• Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
• Partial disposition of shares to satisfy tax withholding obligations.
• The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

Industry Context

This Form 4 filing is a routine disclosure of an insider's planned stock transactions and does not directly relate to broader industry trends or competitive landscape. However, in the biotechnology and pharmaceutical sectors, insider sentiment can sometimes be scrutinized for insights into company prospects, though 10b5-1 plans mitigate immediate concerns.

Related Party Transactions

• The reported transactions involve the planned sale of common stock by James C. Hamilton, Chief Medical Officer, which is inherently a related party transaction as it involves an insider of Arrowhead Pharmaceuticals, Inc.

Stakeholder Impact

• Shareholders: May observe a slight increase in available shares on the market due to the planned disposition, though the impact is likely minimal given the pre-planned nature and relatively small volume compared to total outstanding shares. The perception of insider selling could also influence investor sentiment, though the 10b5-1 plan and tax reasons mitigate this.

Next Steps

• The planned sales of common stock by James C. Hamilton are scheduled to occur on January 5, 2026.

Key Dates

Recommendation

The filing details a routine, pre-planned insider stock sale by the Chief Medical Officer, primarily for tax obligations and under a 10b5-1 plan. This type of transaction, especially one reported well in advance of its execution, is generally not indicative of a change in the company's fundamental outlook or a lack of confidence from management. Therefore, it does not provide a strong basis for a 'buy' or 'sell' recommendation, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

Arrowhead Pharmaceuticals, ARWR, Form 4, Insider Trading, Stock Sale, James C Hamilton, Chief Medical Officer, 10b5-1 Plan, Equity Disposition, Biotechnology, Pharmaceuticals